Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Carcinoma, Hepatocellular 59Cholangiocarcinoma 19Carcinoma, Renal Cell 16Biliary Tract Neoplasms 11Stomach Neoplasms 9Thyroid Neoplasms 8Endometrial Neoplasms 8Parkinson Disease 4, Autosomal Dominant Lewy Body 7Neoplasms 7Melanoma 6Uterine Cervical Neoplasms 5Thyroid Carcinoma, Anaplastic 5Neuroendocrine Tumors 5Carcinoma, Non-Small-Cell Lung 5Recurrence 4Ovarian Neoplasms 4Liver Neoplasms 4Thyroid Cancer, Papillary 3Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Neoplasm Metastasis 3Cirrhosis, Familial, with Pulmonary Hypertension 3Brain Neoplasms 3Advanced Biliary Tract Cancer 3Adenocarcinoma, Follicular 3Vulvar Neoplasms 2Uveal Melanoma 2Triple Negative Breast Neoplasms 2Thymoma 2Solid Tumors 2

Interventions

surufatinib 1pembrolizumab 1lenvatinib 1donafenib 1Thyrotropin Alfa 1Sorafenib 1Injections 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Differentiated Thyroid Cancer × lenvatinib × Clear all
NCT04321954 2026-02-27

Lenvatinib in Locally Advanced Invasive Thyroid Cancer

Massachusetts Eye and Ear Infirmary

Phase 2 Active not recruiting
30 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡